Up next

Autoplay

Dendritic Cell Vaccination in Treatment of Relapsed Pediatric AML

2 Views • 07/04/23
Share
Embed
administrator
administrator
Subscribers
0

Despite allogeneic hematopoietic cell transplantation the survival chances in pediatric AML are 50% only. With the developed adjuvant WT1 Cord Blood Derived Dendritic Cell Vaccine the survival chances may increase. The clinical study will start early 2017.
PIs: Dr Jaap Jan Boelens (clinical / translational) and Dr Stefan Nierkens (lab / translational)

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay